secwatch.observer — SEC 8-K summary
======================================

Issuer:     ADC Therapeutics SA (ADCT)
CIK:        0001771910
Form:       8-K
Filed at:   2024-06-14T23:59:59+00:00
Accession:  0000950103-24-008385
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ADC Therapeutics shareholders approve all 12 proposals at 2024 AGM, including director re-elections and compensation
--------------------------------------------------------------------------------

- Shareholders approved management report, annual financial statements, and discharge of directors/executive committee for FY2023.
- All nine directors reelected; compensation committee members, independent proxy, and PwC auditors also reelected.
- Binding approval: board comp cap $2M; fixed exec comp cap $3M (FY2025); variable exec comp cap $10M (FY2024).
- Advisory votes: compensation report and say-on-pay passed; shareholders recommended annual frequency, adopted by company.
- Articles of association amended in six areas including shareholder rights, meetings, and conditional share capital flexibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1771910/000095010324008385/0000950103-24-008385-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1771910/000095010324008385/dp212847_8k.htm
  HTML page:      https://secwatch.observer/filing/0000950103-24-008385

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer